What is driving Gilead's revenue growth in this period?

Gilead's revenue growth is primarily driven by strong sales of its HIV franchise, particularly Viread, which saw significant increases in both the U.S. and international markets. Sales of AmBisome and emerging products like Hepsera and Emtriva also contributed positively. Royalty and contract revenue, notably from Tamiflu, also increased substantially.

How is Gilead managing its expenses, particularly R&D and SG&A?

Gilead is strategically increasing its investments in both R&D and SG&A. R&D expenses rose 20% in the first half of 2004, primarily due to increased headcount and costs associated with developing Truvada and prodrug technology. SG&A expenses increased by 37% in the same period, supporting global marketing efforts for existing products and launch activities for Truvada and Hepsera, and expanding its sales force.

What is the company's financial position regarding cash and debt?

Gilead Sciences maintained a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $975.6 million as of June 30, 2004. The company significantly reduced its interest expense due to the conversion of its 5% convertible subordinated debt in late 2003, leaving only the 2% convertible senior debt outstanding.

Are there any significant non-recurring items impacting the company's net income?

Yes, the company recorded a significant gain of $20.6 million from the fair valuation of EyeTech warrants upon EyeTech's IPO in January 2004, and an additional $2.3 million gain from the sale of EyeTech shares in the second quarter of 2004. These gains positively impacted net income for the period.

GILD 10-Q Quarterly Report Q2 FY2004 — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. (GILD) reported strong financial performance for the second quarter and first half of 2004, demonstrating significant revenue growth driven primarily by its HIV franchise, particularly Viread. The company's total revenues reached $319.7 million for the quarter and $628.8 million for the six months, representing substantial year-over-year increases. This growth translated into improved profitability, with net income of $111.5 million for the quarter and $225.9 million for the six months, a significant turnaround from a net loss in the prior year's comparable period. The company's strong operational cash flow and a healthy cash and marketable securities balance of $975.6 million provide a solid foundation for future investments in research and development and potential strategic acquisitions. Gilead is actively managing its product portfolio, with key products like Viread, AmBisome, Hepsera, and Emtriva showing positive sales trends, alongside early contributions from Truvada. Management anticipates continued growth in its HIV drug sales, supported by the increasing adoption of once-daily treatment regimens.

Key Highlights

1Total revenues grew 30% year-over-year to $319.7 million in Q2 2004 and 49% to $628.8 million in the first half of 2004.
2Net income increased significantly to $111.5 million ($0.49/share diluted) in Q2 2004 and $225.9 million ($0.99/share diluted) in the first half of 2004, a substantial improvement from the prior year's net loss.
3Product sales, driven by Viread and AmBisome, reached $299.3 million in Q2 2004 (up 30%) and $575.9 million in the first half of 2004 (up 49%).
4Cash, cash equivalents, and marketable securities stood at $975.6 million as of June 30, 2004, indicating strong liquidity.
5Research and Development (R&D) expenses increased by 20% to $104.2 million in the first half of 2004, reflecting continued investment in pipeline development.
6Selling, General, and Administrative (SG&A) expenses increased by 37% to $145.0 million in the first half of 2004, supporting global marketing efforts and new product launches.
7The company achieved a significant gain of $20.6 million from the exercise of EyeTech warrants and a further $2.3 million gain from the subsequent sale of EyeTech shares.

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2004

Summary

Key Highlights

Frequently Asked Questions